Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.

Cancer biology & therapy - 1 Jan 2014

Yu Rui, Albarenque Stella Maris, Cool Robbert H, Quax Wim J, Mohr Andrea, Zwacka Ralf M

Abstract excerpt

Current treatment modalities for pancreatic carcinoma afford only modest survival benefits. TRAIL, as a potent and specific inducer of apoptosis in cancer cells, would be a promising new treatment option. However, since not all pancreatic cancer cells respond to TRAIL, further improvements and optimizations are still needed. One strategy to improve the effectiveness of TRAIL-based therapies is to specifically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Pancreatic Neoplasms
Share to Receptors, TNF-Related Apoptosis-Inducing Ligand

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Recombinant Proteins

Share to TNF-Related Apoptosis-Inducing Ligand

Share to Transfection

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 25482930
DOI: 10.4161/15384047.2014.972183
PMCID: PMC4623120

Genes

XIAP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.PMID 25482930Read ↗

A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.Semantic proximity Read ↗

Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants.Semantic proximity Read ↗

DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design.Semantic proximity Read ↗

Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells.Semantic proximity Read ↗

Generation of a novel TRAIL mutant by proline to arginine substitution based on codon bias and its antitumor effects.Semantic proximity Read ↗

Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling.Semantic proximity Read ↗

Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.Semantic proximity Read ↗

TRAIL mutant membrane penetrating peptide alike-MuR6-TR enhances the antitumor effects of TRAIL in pancreatic carcinoma both in vitro and in vivo.Semantic proximity Read ↗

Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.Semantic proximity Read ↗

Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.Semantic proximity Read ↗

TRAIL as a target in anti-cancer therapy.Semantic proximity Read ↗

CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.